Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Oct;62(9):1075-1076.
doi: 10.1111/head.14397. Epub 2022 Sep 16.

A non-oral gepant for acute treatment of migraine

Rebecca Burch  1
Affiliations
Editorial

A non-oral gepant for acute treatment of migraine

Rebecca Burch. Headache. 2022 Oct.
No abstract available

Keywords: acute treatment; gepant; migraine; non-oral treatment; treatment gap.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache. 2007;47(3):355-363.
    1. Lipton RB, Munjal S, Buse DC, et al. Unmet acute treatment needs from the 2017 Migraine in America Symptoms and Treatment Study. Headache. 2019;59(8):1310-1323.
    1. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT[1B/1D] agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668-1675.
    1. Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo controlled, dose-ranging trial. Headache. 2022;62(9):1153-1163.
    1. Houts CR, McGinley JS, Nishida TK, et al. Systematic review of outcomes and endpoints in acute migraine clinical trials. Headache. 2021;61(2):263-275.

MeSH terms

Substances

LinkOut - more resources